BioSpace News Archive

Graybug Vision, Inc. announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022.

Dr. Uzma Samadani, A Minneapolis neurosurgeon renowned for spine tumor resection and complex neurotrauma repair has completed 4 percutaneous navigated spine fusions with the Inspired Spine OLLIF technology.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2022, ended March 31, 2022, after the market close on April 27, 2022.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022.

UTC Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced it will report its financial results for the first quarter and three months ended March 31, 2022 after the stock market closes on Wednesday, May 4, 2022.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, filed its Annual Report on Form 10-K and reported final audited financial results for the fourth quarter and full year ended December 31, 2021.

Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors.